VYGR
Voyager Therapeutics, Inc. NASDAQ Listed Nov 11, 2015$3.77
+1.48%
vs $3.72
Mkt Cap $228.1M
52w Low $2.83
34.7% of range
52w High $5.55
50d MA $3.80
200d MA $4.09
P/E (TTM)
—
EV/EBITDA
—
P/B
1.1x
Debt/Equity
0.2x
ROE
-61.1%
P/FCF
-1.6x
RSI (14)
44.70
ATR (14)
$0.20
Beta
1.38
50d MA
$3.80
200d MA
$4.09
Avg Volume
559.7K
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
75 Sidney Street · Lexington, MA 02139 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 9, 2026 | AMC | -0.54 | -0.46 | +14.8% | 4.11 | +0.0% | +21.7% | -3.0% | +0.4% | -8.4% | -3.1% | — |
| Nov 10, 2025 | AMC | -0.53 | -0.47 | +11.3% | 4.26 | -0.5% | +0.0% | -0.2% | -6.4% | -1.3% | +4.6% | — |
| Aug 6, 2025 | AMC | -0.48 | -0.57 | -18.8% | 3.40 | +0.0% | -5.3% | -2.5% | -1.9% | +10.1% | +7.7% | — |
| May 6, 2025 | AMC | -0.35 | -0.53 | -51.4% | 3.25 | -0.3% | +0.9% | +4.6% | -7.6% | +5.7% | -2.1% | — |
| Mar 11, 2025 | AMC | -0.35 | -0.59 | -68.6% | 3.97 | -4.3% | +2.3% | +0.2% | -4.2% | -0.3% | +0.0% | — |
| Nov 12, 2024 | AMC | -0.45 | -0.16 | +64.4% | 6.83 | +2.8% | -2.0% | -7.0% | -9.3% | -4.4% | -2.2% | — |
| Aug 6, 2024 | AMC | -0.38 | -0.18 | +52.6% | 8.19 | +4.2% | -14.0% | +3.1% | -4.7% | -4.2% | -0.5% | — |
| May 13, 2024 | AMC | -0.44 | -0.20 | +54.5% | 8.48 | +1.8% | +0.0% | +1.1% | +0.7% | -2.3% | +0.2% | — |
| Feb 28, 2024 | AMC | -0.29 | 1.25 | +531.0% | 8.97 | +10.8% | -7.2% | +13.5% | +2.1% | -5.6% | +1.4% | — |
| Nov 6, 2023 | AMC | -0.58 | -0.59 | -1.7% | 6.49 | -2.0% | +5.1% | -0.1% | -6.3% | -0.5% | -1.1% | — |
| Aug 3, 2023 | AMC | -0.59 | -0.51 | +13.6% | 9.31 | +0.9% | -4.9% | -1.9% | +2.4% | +1.8% | +0.9% | — |
| May 9, 2023 | AMC | 0.77 | 2.94 | +281.8% | 10.76 | +0.1% | -8.1% | -0.1% | +5.7% | -0.4% | +9.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.32 | $4.33 | +0.2% | -9.3% | -4.1% | -0.5% | +2.9% | +0.8% |
| Nov 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.26 | $4.30 | +0.9% | -0.2% | -6.4% | -1.3% | +4.6% | +4.1% |
| Sep 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.18 | $4.18 | +0.0% | +0.7% | +1.0% | +0.2% | +5.4% | -4.9% |
| Aug 7 | Wedbush | Maintains | Outperform → Outperform | — | $3.40 | $3.40 | +0.0% | -5.3% | -2.5% | -1.9% | +10.1% | +7.7% |
| Apr 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.06 | $3.17 | +3.6% | -6.9% | +9.1% | -3.9% | +6.0% | +0.6% |
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.06 | $4.10 | +1.0% | +0.2% | -4.2% | -0.3% | +0.0% | +5.1% |
| Mar 13 | Canaccord Genuity | Maintains | Buy → Buy | — | $4.06 | $4.10 | +1.0% | +0.2% | -4.2% | -0.3% | +0.0% | +5.1% |
| Mar 12 | Wells Fargo | Maintains | Overweight → Overweight | — | $3.97 | $3.80 | -4.3% | +2.3% | +0.2% | -4.2% | -0.3% | +0.0% |
| Mar 12 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $3.97 | $3.80 | -4.3% | +2.3% | +0.2% | -4.2% | -0.3% | +0.0% |
| Mar 12 | Wedbush | Maintains | Outperform → Outperform | — | $3.97 | $3.80 | -4.3% | +2.3% | +0.2% | -4.2% | -0.3% | +0.0% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.08 | $4.13 | +1.2% | -4.2% | +1.3% | +4.8% | -0.2% | +2.9% |
| Jan 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.62 | $5.60 | -0.4% | +0.2% | -0.5% | -1.4% | +1.6% | -2.9% |
| Nov 14 | Canaccord Genuity | Maintains | Buy → Buy | — | $6.69 | $6.73 | +0.6% | -7.0% | -9.3% | -4.4% | -2.2% | +1.7% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.69 | $6.73 | +0.6% | -7.0% | -9.3% | -4.4% | -2.2% | +1.7% |
| Oct 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.43 | $6.44 | +0.2% | +2.3% | +2.6% | +4.0% | +0.7% | -3.3% |
| Aug 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.66 | $6.75 | +1.4% | +4.4% | -1.2% | -2.9% | +1.9% | +1.2% |
| Aug 7 | Wedbush | Maintains | Neutral → Neutral | — | $8.19 | $8.53 | +4.2% | -14.0% | +3.1% | -4.7% | -4.2% | -0.5% |
| Jul 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.26 | $9.27 | +0.1% | -0.8% | -5.5% | -4.4% | -4.0% | +2.8% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.57 | $8.65 | +0.9% | +0.7% | -2.3% | +0.2% | -0.1% | -1.7% |
| May 15 | Oppenheimer | Maintains | Outperform → Outperform | — | $8.48 | $8.52 | +0.5% | +1.1% | +0.7% | -2.3% | +0.2% | -0.1% |
| May 14 | Wedbush | Maintains | Neutral → Neutral | — | $8.48 | $8.63 | +1.8% | +0.0% | +1.1% | +0.7% | -2.3% | +0.2% |
| Jan 2 | Wells Fargo | Upgrade | Equal Weight → Overweight | — | $8.44 | $10.53 | +24.8% | +6.6% | +19.7% | +0.7% | -18.4% | +2.4% |
| Aug 7 | Oppenheimer | Maintains | Outperform → Outperform | — | $8.85 | $8.77 | -1.0% | -1.9% | +2.4% | +1.8% | +0.9% | +2.3% |
| May 10 | Canaccord Genuity | Maintains | Buy → Buy | — | $10.76 | $10.77 | +0.1% | -8.1% | -0.1% | +5.7% | -0.4% | +9.3% |
| May 10 | Truist | Maintains | Buy → Buy | — | $10.76 | $10.77 | +0.1% | -8.1% | -0.1% | +5.7% | -0.4% | +9.3% |
| Mar 10 | Oppenheimer | Maintains | Outperform → Outperform | — | $7.91 | $8.25 | +4.3% | -4.9% | +4.7% | +5.3% | -3.3% | +2.4% |
| Nov 3 | Chardan Capital | Maintains | Neutral → Neutral | — | $3.89 | $3.89 | +0.0% | +2.6% | -5.3% | +0.5% | -3.9% | -1.1% |
| Oct 7 | Baird | Upgrade | Neutral → Outperform | — | $3.87 | $3.94 | +1.8% | -0.8% | +44.5% | -13.5% | -4.0% | -1.7% |
| Apr 19 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $4.56 | $4.56 | +0.0% | -2.0% | +4.5% | +2.6% | -1.9% | -0.6% |
| Feb 26 | Baird | Downgrade | Outperform → Neutral | — | $6.23 | $5.90 | -5.3% | -9.0% | +5.3% | -5.0% | -2.3% | +0.7% |
| Feb 3 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $8.00 | $7.00 | -12.5% | -6.4% | -0.3% | -0.3% | +3.4% | -2.1% |
| Feb 3 | BTIG | Downgrade | Buy → Neutral | — | $8.00 | $7.00 | -12.5% | -6.4% | -0.3% | -0.3% | +3.4% | -2.1% |
| Feb 3 | Wedbush | Downgrade | Outperform → Neutral | — | $8.00 | $7.00 | -12.5% | -6.4% | -0.3% | -0.3% | +3.4% | -2.1% |
| Nov 11 | Oppenheimer | Downgrade | Outperform → Perform | — | $8.60 | $8.71 | +1.3% | +2.9% | -2.5% | -0.9% | +2.2% | -0.3% |
| Nov 10 | Raymond James | Downgrade | Strong Buy → Outperform | — | $11.20 | $10.01 | -10.6% | -23.2% | +2.9% | -2.5% | -0.9% | +2.2% |
| Nov 10 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $11.20 | $10.01 | -10.6% | -23.2% | +2.9% | -2.5% | -0.9% | +2.2% |
| Aug 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.33 | $10.83 | -4.4% | -8.6% | +4.4% | +1.7% | +1.8% | -0.1% |
| Apr 15 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $10.25 | $9.72 | -5.2% | -6.2% | -0.3% | +6.5% | +2.1% | +0.8% |
| Mar 30 | Nomura | Maintains | Buy → Buy | — | $9.05 | $9.11 | +0.7% | -3.3% | +4.6% | -12.0% | +8.1% | -6.6% |
| Mar 19 | Benchmark | Maintains | Buy → Buy | — | $7.16 | $7.26 | +1.4% | +5.6% | -8.7% | +4.6% | +18.1% | +8.1% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.58 | $12.31 | +6.3% | +4.3% | -3.6% | -5.8% | -6.9% | +6.5% |
| Mar 4 | Wedbush | Maintains | Outperform → Outperform | — | $11.58 | $12.31 | +6.3% | +4.3% | -3.6% | -5.8% | -6.9% | +6.5% |
| Mar 4 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $11.58 | $12.31 | +6.3% | +4.3% | -3.6% | -5.8% | -6.9% | +6.5% |
| Feb 6 | Oppenheimer | Maintains | Outperform → Outperform | — | $12.66 | $13.10 | +3.5% | +7.6% | -4.8% | +0.0% | +1.9% | +2.3% |
| Oct 11 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $14.93 | $15.10 | +1.1% | +1.5% | -1.8% | +3.4% | -1.5% | +1.6% |
| Jul 12 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $25.67 | $26.02 | +1.4% | -0.7% | +0.6% | -3.5% | -3.2% | +2.5% |
| Mar 6 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $17.76 | $17.99 | +1.3% | -5.3% | +3.0% | -0.1% | +7.3% | -5.7% |
| Nov 15 | Raymond James | Upgrade | Outperform → Strong Buy | — | $11.25 | $12.43 | +10.5% | +8.3% | +2.2% | -6.9% | +0.2% | +2.2% |
| Nov 8 | Baird | Maintains | Outperform → Outperform | — | $13.99 | $11.20 | -19.9% | -12.0% | +0.0% | -6.6% | +2.5% | -4.7% |
| Jun 4 | H.C. Wainwright | Maintains | Buy → Buy | — | $20.41 | $22.27 | +9.1% | +3.6% | +2.4% | +3.9% | +0.0% | -0.6% |
No insider trades available.
8-K · 5.03
! Medium
Voyager Therapeutics, Inc. -- 8-K 5.03: Amendment to Articles / Bylaws
Jun 10
8-K · 5.02
!!! Very High
Voyager Therapeutics, Inc. -- 8-K 5.02: Executive Change
Voyager Therapeutics replaced CFO Nathan Jorgensen while elevating Robin Swartz to COO and adding Amy Quinlan as director, signaling operational restructuring effective May 2026.
Apr 21
8-K
Voyager Therapeutics, Inc. -- 8-K Filing
Voyager Therapeutics expects 2026 to deliver pivotal data on tau-targeting Alzheimer's treatments, initiate clinical trials for IV-delivered gene therapies, and advance its nonviral delivery platform.
Mar 9
8-K
Voyager Therapeutics, Inc. -- 8-K Filing
Voyager Therapeutics disclosed SEC filing details regarding its emerging growth company status, which may affect regulatory reporting requirements and compliance obligations for investors.
Feb 12
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Millennium Management | 3,428,571 | $13M | Added | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 2,283,253 | $9M | New | Mar 2026 |
| 3 | Opaleye Management Inc. | 1,196,904 | $5M | New | Dec 2025 |
| 4 | Morgan Stanley | 1,088,228 | $4M | Reduced | Dec 2025 |
| 5 | Vanguard Portfolio Management Llc | 725,769 | $3M | New | Mar 2026 |
| 6 | Two Sigma Investments, Lp | 615,660 | $2M | Added | Mar 2026 |
| 7 | Renaissance Technologies Llc | 578,024 | $2M | Added | Mar 2026 |
| 8 | Northern Trust Corp | 384,843 | $1M | Added | Mar 2026 |
| 9 | Citadel Advisors Llc | 364,664 | $1M | Reduced | Mar 2026 |
| 10 | Jpmorgan Chase & Co | 276,867 | $1M | Reduced | Mar 2026 |
| 11 | Altshuler Shaham Ltd | 273,925 | $1M | New | Mar 2026 |
| 12 | Point72 Asset Management | 268,223 | $1M | Added | Mar 2026 |
| 13 | Acadian Asset Management Llc | 248,871 | $957K | Added | Mar 2026 |
| 14 | Aqr Capital Management Llc | 232,681 | $898K | Added | Mar 2026 |
| 15 | Woodline Partners Lp | 193,984 | $749K | New | Mar 2026 |
| 16 | Fmr Llc | 163,682 | $632K | Added | Mar 2026 |
| 17 | Jane Street Group, Llc | 149,747 | $589K | Reduced | Dec 2025 |
| 18 | Bank Of New York Mellon Corp | 139,770 | $540K | — | Mar 2026 |
| 19 | Privium Fund Management B.v. | 120,000 | $463K | Added | Mar 2026 |
| 20 | Invesco Ltd. | 119,171 | $460K | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$228.1M
Enterprise Value
$21.9M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.02x
P/B
1.13x
P/S
6.07x
P/FCF
-1.62x
EV/EBITDA
—
Shares Out
58.7M
Financials (TTM)
Revenue
$36.5M
Net Income
-$116.6M
EBITDA
-$112.5M
Free Cash Flow
-$135.1M
Op Cash Flow
-$132.5M
EPS Basic
$-2.04
EPS Diluted
$-1.98
EPS Forward
$-1.81
Gross Margin
-86.7%
Op Margin
-349.2%
Net Margin
-319.6%
Balance Sheet
Total Assets
$252.3M
Total Liab.
$56.2M
Total Equity
$196.1M
Cash
$196.4M
LT Debt
$0
Book Value/Sh
$3.34
Debt/Equity
0.19x
Current Ratio
7.64
Quick Ratio
7.64
Returns & Growth
ROE
-61.1%
ROA
-47.5%
ROIC
-56.4%
Rev Growth YoY
-49.5%
EPS Growth YoY
-80.5%
Price Returns
2W
-8.7%
1M
+3.8%
3M
-5.6%
6M
-5.4%
12M
+41.2%
Technicals
52W High
$5.55
52W Low
$2.83
50d MA
$3.80
200d MA
$4.09
RSI (14)
44.70
ATR (14)
$0.20
Beta
1.38
Avg Volume
560K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$14.40
High
$18.00
Low
$8.00
Median
$18.00
Data updated apr 27, 2026 8:34am
· Source: financialmodelingprep.com